FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.
Thomson
A W
AW
Transplant Institute, University of Pittsburgh, PA 15213.
Carroll
P B
PB
McCauley
J
J
Woo
J
J
Abu-Elmagd
K
K
Starzl
T E
TE
Van Thiel
D H
DH
D000328:Adult; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002761:Cholangitis / Q000188:drug therapy; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004066:Digestive System Diseases / Q000188:drug therapy; D004195:Disease Models, Animal; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D051381:Rats; D013552:Swine; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D016572:Cyclosporine; D016559:Tacrolimus